Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 8/20 | 0.53 |
| ▸ | ORAI1 | Q96D31 | 8/20 | 0.53 |
| ▸ | IL2 | P60568 | 7/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | ESRRG | P62508 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15528238 | 0.91 | IL2 (0.49) | STIM1ORAI1IL2TNFESRRG | |
| SCHEMBL15528184 | 0.90 | STIM1 (0.48) | STIM1ORAI1IL2TNFESRRG | |
| SCHEMBL15528586 | 0.90 | IL2 (0.50) | STIM1ORAI1IL2TNFESRRG | |
| SCHEMBL2731604 | 0.88 | IL2 (0.63) | STIM1ORAI1IL2TNFESRRG | |
| SCHEMBL15528216 | 0.88 | STIM1 (0.47) | STIM1ORAI1IL2TNFESRRG | |
| SCHEMBL15205665 | 0.88 | IL2 (0.55) | STIM1ORAI1IL2TNFESRRG | |
| SCHEMBL2732760 | 0.88 | IL2 (0.58) | STIM1ORAI1IL2TNFESRRG | |
| SCHEMBL2733691 | 0.85 | IL2 (0.58) | STIM1ORAI1IL2TNFESRRG | |
| SCHEMBL2733154 | 0.85 | IL2 (0.52) | STIM1ORAI1IL2TNFESRRG | |
| SCHEMBL15528210 | 0.84 | IL2 (0.43) | STIM1ORAI1IL2TNFESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | claimed |
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | claimed |
| EP-2844655-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | Lupin Limited (IN) | 2015-03-11 | — | — | EP | claimed |
| WO-2013164769-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-11-07 | — | — | WO | claimed |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-9399638-B2 | Substituted pyridine compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-07-26 | — | — | US | disclosed |
| US-9399638-B2 | Substituted pyridine compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-07-26 | — | — | US | disclosed |
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | STIM1 29/4885ORAI1 1/4885IL2 2982/4885 |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | STIM1 29/4885ORAI1 1/4885IL2 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.